InStim is designed to read real time inflammatory and anti-inflammatory cytokines in body organs and then adjust real time up or down cytokine levels to get inflammation in balance and under control to promote optimal healing and long term organ health and function.

Press Release – Santa Monica, CA – October 6th, 2017 – Today the team at Leonhardt’s Launchpads announced the launch of a new startup InStim that is focusing on the development of bioelectric treatments for the customized real time management of inflammation.

The original InStim device design has these primary components for inflammation control therapy:

  1. Wireless means to read real time inflammatory and anti-inflammatory cytokine levels in an organ or blood flow.
  2. Wireless bioelectric signals direct to specific organ regions to manage the control of inflammation with real time customized delivery of signals for balancing cytokine levels.
  3. Bioelectric signals delivered via the nervous and cardiovascular system to manage total body electrical potentials balance.

“Inflammation cannot be managed with a single drug or single bioelectric signal. The body produces inflammation to promote healing and the right cytokines at the right time in the right sequence greatly aide in healing. The very same cytokines at the wrong time in the wrong sequence and at the wrong levels for the wrong duration can cause detrimental damage to health. Our invention is the first to read real time these inflammatory and anti-inflammatory cytokines and to deliver multiple cytokine up or down regulation real time to best attempt to gain the right inflammatory balance.” states Howard J. Leonhardt, Inventor, Founder and CEO of InStim and Leonhardt’s Launchpads.

“Chronic Inflammation contributes to the downward spiral of many disease states and conditions. Our team is working to apply this inflammation management tool to chronic heart failure treatment in partnership with BioLeonhardt, for concussion recovery in partnership with CerebraCell and with PancreaCell for pancreas health recovery from pancreatitis, just to name three potential applications of many. We look forward to proving out in well designed translational research studies that inflammation is best treated with a real time customized and constantly adapting treatment modality.” states Dr. Leslie Miller, Chief Medical Officer, InStim and Leonhardt’s Launchpads.

InStim is a device that in response to a subject’s inflammatory marker levels, delivers bioelectric protein expression signals to the subject’s tissue so as to upregulate and/or downregulate select protein expression(s) in the subject so as to balance inflammation in the subject.

The InStim device comprises: a power source, an input or several inputs to determine the subject’s inflammatory markers, and means for delivering bioelectric signals to the subject’s tissue, wherein the device utilizes the electrical signals to precisely control select protein expression(s) in the tissue on demand.

“Chronic inflammation increases cancer risk. It is clear from numerous studies that cell signaling elicited by inflammatory cytokines promotes tumor development. We look forward now to carefully studying this breakthrough pioneering real time inflammation management technology from InStim and CancerCell in treating cancer” stated Dr. Santosh Kesari, Chief Medical Advisor for CancerCell and CerebraCell and Chair and Professor, Department of Translational Neuro-oncology and Neurotherapeutics, John Wayne Cancer Institute. He is also Director of Neuro-oncology, Providence Saint John’s Health Center and leads the Pacific Neuroscience Research Center at the Pacific Neuroscience Institute in Santa Monica, California Dr. Kesari is also involved with brain injury recovery application studies for the InStim and CerebraCell technoloigies.

About InStim: InStim is an early stage startup incubating in the Leonhardt’s Launchpads innovation accelerators in Santa Monica and Playa Vista, California focused on customized inflammation management with bioelectric stimulation. Leonhardt’s Launchpads Utah, Inc. is also participating in advancing this technology platform forward at our research lab in Utah @ BioInnovations Gateway. InStim is licensing its technology to other startups within Leonhardt’s Launchpads accelerators for specific organ applications such as CerebraCell for brain injury recovery, PancreaCell for pancreas regeneration recovery from pancreatitis, CancerCell for bioelectric cancer treatments and BioLeonhardt for chronic heart failure recovery.

About Leonhardt’s Launchpads: Founded by Leonhardt Ventures in 2008 Leonhardt’s Launchpads focuses on launching startups focused on Regenerative Medtech and Regenerative Economy innovations. 30 startups currently are within the Leonhardt’s Launchpads accelerators at four locations in Santa Monica, Playa Vista and Petaluma in California and Salt Lake City, Utah. Leonhardt’s Launchpads’ majority of startups are all based on Leonhardt Ventures’ patented technology platform of bioelectric stimulator and when needed also a micro infusion pump re-filled daily or weekly with a fifteen component mixed stem cell + growth factors organ regeneration composition. Leonhardt’s Launchpads accelerators are operated by Cal-X Stars Business Accelerator, Inc. a California C corporation majority owned by Leonhardt Ventures (Leonhardt Vineyards LLC DBA Leonhardt Ventures). Leonhardt’s Launchpads Utah, Inc. is a stand alone C corporation in Salt Lake City, Utah – The business model of Leonhardt’s Launchpads is to advance startups through to first-in-man clinical data and then seek out a strategic specific organ focused partner.

About Leonhardt Ventures: Founded in 1982 by inventor Howard J. Leonhardt has led the development of a number of leading organ regeneration and recovery products including the world’s leading stent graft system for aortic aneurysm repair. Over 500,000 patients to date have been treated with Leonhardt inventions. See for more information including links to web sites of all our startups. Registered as Leonhardt Vineyards LLC DBA Leonhardt Ventures since 2005. Click here for Leonhardt’s Ventures 2017 Annual Report >

Cautionary Statement: Leonhardt’s Launchpads and Leonhardt Ventures specialize in early stage development of organ regeneration and recovery technologies with a very small staff and very small budget compared to competitors in the sector. The technologies are brand new and are unproven for safety and efficacy. By nature of this specialization the investment risk is very high and is not meant for “nest egg” savings and is reserved only for sophisticated accredited investors with experience in these type of investments. Some statements may be forward looking and information may change. Information on linked web sites may be outdated and is prone to errors due to the small staff and budget to maintain their accuracy and updates. All of our patents are subject to upkeep with maintenance fees. All of our agreements with third parties are subject to conditions that must be met to keep them active and valid. If you have any questions requiring clarification of any information or updated information please contact us at the below email addresses or phone voice mail.

Leonhardt’s Launchpads is lead by a team of over 100 experienced members – which includes a scientific advisory board – comprised world opinion leaders in their fields of expertise